Northwest Biotherapeutics (NWBO) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$16.9 million.
- Northwest Biotherapeutics' Income towards Parent Company fell 35.54% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 541.68%. This contributed to the annual value of -$74.3 million for FY2024, which is 2226.54% down from last year.
- Latest data reveals that Northwest Biotherapeutics reported Income towards Parent Company of -$16.9 million as of Q3 2025, which was down 35.54% from -$16.6 million recorded in Q2 2025.
- Northwest Biotherapeutics' Income towards Parent Company's 5-year high stood at -$11.7 million during Q3 2021, with a 5-year trough of -$22.5 million in Q2 2022.
- In the last 5 years, Northwest Biotherapeutics' Income towards Parent Company had a median value of -$16.9 million in 2024 and averaged -$16.8 million.
- Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' Income towards Parent Company was 7818.48% (2021), while the steepest drop was 14848.66% (2021).
- Quarter analysis of 5 years shows Northwest Biotherapeutics' Income towards Parent Company stood at -$11.8 million in 2021, then crashed by 64.0% to -$19.4 million in 2022, then grew by 15.54% to -$16.4 million in 2023, then decreased by 28.09% to -$21.0 million in 2024, then rose by 19.28% to -$16.9 million in 2025.
- Its Income towards Parent Company was -$16.9 million in Q3 2025, compared to -$16.6 million in Q2 2025 and -$18.9 million in Q1 2025.